GlobeNewswire

Fingerprint Cards AB: invitation to the third quarter 2019 results presentation

Share

Fingerprint Cards AB (Fingerprints™) will host a telephone conference and webcast presentation of its third quarter 2019 results, on November 15, 2019 at 09:00 CET. The report will be published at 07:00 CET the same day.

Fingerprints’ CEO Christian Fredrikson will present the report together with CFO Per Sundqvist in a combined webcast and telephone conference. The presentation will be held in English.

Time: Friday, November 15, 2019 at 09:00 CET.
Location: combined webcast and telephone conference.

The report will be available at https://www.fingerprints.com/

The webcast and the presentation material can be accessed through https://engage.vevent.com/rt/fingerprints/index.jsp?seid=153 where it is also possible to ask questions.

For media and analysts: The telephone conference dial-in is +44 (0) 2071 928000 (international participants) or 08-506 921 80 (Swedish participants). Please state conference ID 8450519.

About Fingerprints
Fingerprint Cards AB (Fingerprints) – the world’s leading biometrics company, with its roots in Sweden. We believe in a secure and seamless universe, where you are the key to everything. Our solutions are found in hundreds of millions of devices and applications, and are used billions of times every day, providing safe and convenient identification and authentication with a human touch. For more information visit our website, read our blog, and follow us on Twitter. Fingerprints is listed on Nasdaq Stockholm (FING B).

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Úlfar Freyr Stefánsson appointed Chief Risk Officer of Arion Bank – Gísli S. Óttarsson leaves the Bank25.5.2020 18:50:52 CESTPress release

Úlfar Freyr Stefánsson has been appointed Chief Risk Officer of Arion Bank. Úlfar is taking over from Gísli S. Óttarsson who will be leaving the Bank after having been Chief Risk Officer and a member of the Bank’s executive committee since 2009. Gísli will step down at the end of the month but will continue to work in an advisory capacity for the Bank. Úlfar joined the Bank’s Risk Management division in 2013 after having worked at Kaupthing since 2010, where his positions included head of risk management. Úlfar was Head of Portfolio Risk at Arion Bank from 2013 to 2015, when he took over as Head of Balance Sheet Risk. Úlfar has a doctorate in mathematics from Georgia Institute of Technology and a master’s from the same institution. He also has a BSc in mathematics from the University of Iceland and is a certified securities broker. Benedikt Gíslason, CEO of Arion Bank: “I would like to thank Gísli for his excellent work and vital contribution to the Bank over the years. His successor a

PRESS RELEASE: NACON: 2019/20 ANNUAL RESULTS25.5.2020 18:34:13 CESTPress release

Press release Lesquin, 25 May 2020, 18 :00 hrs Strong growth of profitability in 2019/20: ·Current Operating Profit: 22,6 M€ (+80,3%) ·Net Résult: 15,3 M€ (+41,8%) Outlook 2020/21 : ·Sales between 140 and 150 M€ ·Current Operating Profit Rate: 18% NACON (ISIN FR0013482791) today releases its audited consolidated results for the financial year closing on 31 March 2020 as approved by its Board of directors on 25 May 2020. Consolidated in M€ IFRS03/2020 (4)03/2019 (3) Var.Sales129.4113.1+14.4%Gross margin (1) In % of Sales EBITDA (2) In % of Sales 79.1 61.1% 48.4 37.4% 62.4 55.2% 33.4 29.5%+26.7% +45.0%Result from current operations In % of Sales Non recurrent items (including Bonus Shares)22.6 17.5% (2.0)12.5 11.1% 0.8 +80.3% Operating result In % of Sales20.6 15.9%13.4 11.8%+53.8%Financial result Including currency gain (loss)(0.6)(0.4) Earnings before tax In % of Sales20.0 15.4%13.0 11.5%+53.6%Tax(4.7)(2.2)Net result for the period In % of Sales15.3 11.8%10.8 9.5% +41.8% (1) Gross marg

PRESS RELEASE: BIGBEN: 2019/20 Annual Résults25.5.2020 18:15:16 CESTPress release

Press release Lesquin, 25 May 2020 18:00 2019/20 Annual Résults: ·Sales: 263.5 M€ (+7.3%) ·Current Operating Income: 23.7 M€ (+9.0%) ·Net Résult: 16.2 M€ (-6.3%) New « BIGBEN 2023 » plan: ·2022/23 sales: 350 M€ ·2022/23 Current Operating Income Rate: 13% BIGBEN INTERACTIVE (ISIN FR0000074072) today releases its audited consolidated results for the financial year closing on 31 March 2020 as approved by its Board of directors on 25 May 2020. Consolidated in M€ IFRS03/202003/2019 Change.Sales263.5245.5+7.3%Gross margin (1) In % of Sales EBITDA (2) In % of Sales 108.9 41,3% 52.5 19.9% 97.6 39.8% 44.9 18.3%+11.6% +16.8%Result from current operations In % of Sales Non recurrent items (including Bonus Shares)23.7 9.0% (2.9)21.7 8.9% 0.6 +9.0% Operating result In % of Sales20.8 7.9%22.3 9.1%-6.7%Financial result Including currency gain (loss)(1.1) 0.30.5 1.5 Earnings before tax In % of Sales19.7 7.5%22.8 9.3%-13.3%Tax(3.5)(5.4)Net result for the period In % of Sales16.2 6.2%17.3 7.1% -6.3% Of

Inventiva secures a new patent for lanifibranor in China expanding the protection of its lead product candidate25.5.2020 17:45:00 CESTPress release

New patent granted by the CNIPA is directed at the use of lanifibranor for the treatment of several fibrotic diseases, including NASH, and expires in June 2035 The patent expands the existing patent portfolio for lanifibranor in the world’s second largest pharmaceutical market1 Daix (France), May 25, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the China National Intellectual Property Administration (CNIPA) granted a new patent directed at the use of lanifibranor for the treatment of several fibrotic diseases in China until June 2035. This new patent covers, among others, the use of the Company’s lead product candidate lanifibranor for the treatment of NASH, hepatic fibrosis, chronic renal failure and fibrotic pulmonary disorder. It thereby expands the

CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER25.5.2020 16:20:00 CESTPress release

Bid procedure on 27 May 2020 Certificate: Commercial paper issued in SEK by non-financial companies with a registered office in Sweden and with a remaining maturity of up to six months on the Bid date, i.e. with the maturity date on 27 November 2020 at the latest. Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after 18 May 2020. Bids: Counterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se. Bid date: Wednesday 27 May 2020 Bid time: 0900-0930 hours (CEST) on the Bid date Requested volume: (corresponding nominal amount) SEK 4 billion Highest permitted bid volume: (corresponding nominal amount) The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in e